In a recent bid Syneos Health Inc. [SYNH] faced a contemporary bid of $61.24 yielding a -1.08% decline where 1.57 million shares have exchanged hands over the last week. SYNH amount got a fall by -6.82% or -$4.48 versus $65.72 at the end of the prior session. This change led market cap to move at 6.75B, putting the price 104.00% below the 52-week high and -17.52% above the 52-week low. The company’s stock has a normal trading capacity of 1.57 million shares while the relative volume is 5.88.
On 2, December 2020, Syneos Health Announces Pricing of Secondary Offering of Common Stock. According to news published on Yahoo Finance, Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 6,000,000 shares of the Company’s common stock (the “Offering”) at a price to the public of $61.90 per share. Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the selling stockholders in the Offering. The Offering is expected to close on December 3, 2020, subject to customary closing conditions.
Analyst Birdseye View:
The most recent analyst activity for Syneos Health Inc. [NASDAQ:SYNH] stock was on October 01, 2020, when it was Upgrade with a Buy rating from Goldman, which also raised its 12-month price target on the stock from $69 to $75. Before that, on October 06, 2020, Mizuho Recapitulated a Buy rating and elevated its amount target to $65. On March 30, 2020, Goldman Downgrade a Neutral rating and plunged its price target on this stock from $79 to $45. On January 07, 2020, Citigroup Initiated a Buy rating and increased its price target to $75. On October 19, 2018, William Blair Upgrade an Outperform rating. On October 09, 2018, UBS Initiated a Buy rating. On October 04, 2018, Evercore ISI Initiated an Outperform rating and boosted its target amount on this stock to $58.
In the past 52 weeks of trading, this stock has oscillated between a low of $30.02 and a peak of $74.25. Right now, the middling Wall Street analyst 12-month amount mark is $75.50. At the most recent market close, shares of Syneos Health Inc. [NASDAQ:SYNH] were valued at $61.24. According to the average price forecast, investors can expect a potential return of 0.56%.
Syneos Health Inc. [NASDAQ:SYNH] most recently reported quarterly sales of 1.1 billion, which represented growth of -6.60%. This publicly-traded organization’s revenue is $194,826 per employee, while its income is $5,469 per employee. This company’s Gross Margin is currently 22.50%, its Operating Margin is 6.30%, its Pretax Margin is +2.18, and its Net Margin is +2.81. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 1.78, 4.46, 5.87 and 2.29 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 49.08 and the whole liability to whole assets at 39.17. It shows enduring liability to the whole principal at 47.16 and enduring liability to assets at 0.38 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 64.76 points at 1st support level, the second support level is making up to 63.79. But as of 1st resistance point, this stock is sitting at 66.84 and at 67.95 for 2nd resistance point.
Syneos Health Inc. [SYNH] reported its earnings at $1.04 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $0.91/share signifying the difference of 0.13 and 14.30% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were $0.58 calling estimates for $0.48/share with the difference of 0.1 depicting the surprise of 20.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Syneos Health Inc. [NASDAQ:SYNH] is 1.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.11. Now if looking for a valuation of this stock’s amount to sales ratio it’s 1.34, it’s amount to book ratio is 2.04 and showing 36.11 of P/E (TTM) ratio.
The most recent insider trade was by Meggs Jason M., Chief Financial Officer, and it was the sale of 4062.0 shares on Nov 27. Meggs Jason M., the Chief Financial Officer, completed a sale of 1938.0 shares on Nov 24. On Nov 18, KEEFE MICHELLE, Pres., Commercial Solutions, completed a sale of 856.0 shares.